Compounds > sigetin, dipotassium salt
Page last updated: 2024-12-06

sigetin, dipotassium salt

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

sigetin: synthetic estrogenic substance; russian drug; RN given is for (R,S)-isomer; sigetin is for di-K salt [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID26078
MeSH IDM0307746

Synonyms (20)

Synonym
4,4'-(1,2-diethyl-1,2-ethanediyl)bisbenzenesulfonic acid dipotassium salt
benzenesulfonic acid, 4,4'-(1,2-diethyl-1,2-ethanediyl)bis-, dipotassium salt
bibenzyl-4,4'-disulfonic acid, alpha,alpha'-diethyl-, dipotassium salt
dipotassium meso-n,n-disulfo-3,4-diphenylhexane
3563-47-1
meso-alpha,alpha'-diethylbibenzyl-4,4'-disulfonic acid dipotassium salt
bibenzyl-4,4'-disulfonic acid, alpha,alpha'-diethyl-, dipotassium salt, meso-
benzenesulfonic acid, 4,4'-((1r,2s)-1,2-diethyl-1,2-ethanediyl)bis-, dipotassium salt, rel-
sygetin
disulfo-meso-4,4-diphenylhexane dipotassium salt
(r*,s*)-4,4'-(1,2-diethyl-1,2-ethanediyl)bis(benzenesulfonic acid) dipotassium
benzenesulfonic acid, 4,4'-(1,2-diethyl-1,2-ethanediyl)bis-, dipotassium salt, (r*,s*)-
sigetin
dipotassium-meso-n,n-disulfo-3,4-diphenylhexane
unii-9t83v1maej
9t83v1maej ,
dipotassium 4,4'-(hexane-3,4-diyl)di(benzene-1-sulfonate)
DTXSID50928902
3563-47-1 (potassium)
dipotassium;4-[4-(4-sulfonatophenyl)hexan-3-yl]benzenesulfonate
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-199016 (94.12)18.7374
1990's1 (5.88)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.97

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.97 (24.57)
Research Supply Index3.30 (2.92)
Research Growth Index4.27 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.97)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
dipyridamole
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752). dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.		1.9810piperidines;
pyrimidopyrimidine;
tertiary amino compound;
tetrol		adenosine phosphodiesterase inhibitor;
EC 3.5.4.4 (adenosine deaminase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent
berotek
Fenoterol: A synthetic adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic.. fenoterol : A member of the class resorcinols that is 5-(1-hydroxyethyl)benzene-1,3-diol in which one of the methyl hydrogens is replaced by a 1-(4-hydroxyphenyl)propan-2-amino group. A beta2-adrenergic agonist, it is used (as the hydrobromide salt) as a bronchodilator in the management of reversible airway obstruction.		1.9610resorcinols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent;
tocolytic agent
reserpine
Reserpine: An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.. reserpine : An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria.		1.9310alkaloid ester;
methyl ester;
yohimban alkaloid		adrenergic uptake inhibitor;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
first generation antipsychotic;
plant metabolite;
xenobiotic
estrone
Hydroxyestrones: Estrone derivatives substituted with one or more hydroxyl groups in any position. They are important metabolites of estrone and other estrogens.		1.941017-oxo steroid;
3-hydroxy steroid;
phenolic steroid;
phenols		antineoplastic agent;
bone density conservation agent;
estrogen;
human metabolite;
mouse metabolite
diphenyl
diphenyl: RN given refers to unlabeled cpd; structure		1.9310aromatic fungicide;
benzenes;
biphenyls		antifungal agrochemical;
antimicrobial food preservative
2-methylpentane
Hexanes: Six-carbon saturated hydrocarbon group of the methane series. Include isomers and derivatives. Various polyneuropathies are caused by hexane poisoning.		1.9310alkane
n-hexane
hexane : An unbranched alkane containing six carbon atoms.		1.9310alkane;
volatile organic compound		neurotoxin;
non-polar solvent
xanthinol niacinate
Xanthinol Niacinate: A vasodilator used in peripheral vascular disorders and insufficiency. It may cause gastric discomfort and hypotension.		1.9810
diethylstilbestrol
Diethylstilbestrol: A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed). diethylstilbestrol : An olefinic compound that is trans-hex-3-ene in which the hydrogens at positions 3 and 4 have been replaced by p-hydroxyphenyl groups.		2.3620olefinic compound;
polyphenol		antifungal agent;
antineoplastic agent;
autophagy inducer;
calcium channel blocker;
carcinogenic agent;
EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
endocrine disruptor;
xenoestrogen
dienestrol
Dienestrol: A synthetic, non-steroidal estrogen structurally related to stilbestrol. It is used, usually as the cream, in the treatment of menopausal and postmenopausal symptoms.. dienestrol : An olefinic compound that is hexa-2,4-diene substituted by 4-hydroxyphenyl groups at positions 3 and 4 respectively.		1.9610
ConditionIndicatedRelationship StrengthStudiesTrials
Adenohypophyseal Diseases
[description not available]		01.9310
Pituitary Diseases
Disorders involving either the ADENOHYPOPHYSIS or the NEUROHYPOPHYSIS. These diseases usually manifest as hypersecretion or hyposecretion of PITUITARY HORMONES. Neoplastic pituitary masses can also cause compression of the OPTIC CHIASM and other adjacent structures.		01.9310
Suffocation
[description not available]		01.9410
Asphyxia Neonatorum
Respiratory failure in the newborn. (Dorland, 27th ed)		01.9410
Anoxia, Fetal
[description not available]		02.8740
Asphyxia
A pathological condition caused by lack of oxygen, manifested in impending or actual cessation of life.		01.9410
Fetal Hypoxia
Deficient oxygenation of FETAL BLOOD.		02.8740
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		03.75110
Fetal Growth Restriction
[description not available]		02.6630
Endometrial Diseases
[description not available]		01.9610
Placenta Diseases
Pathological processes or abnormal functions of the PLACENTA.		01.9610
Fetal Growth Retardation
Failure of a FETUS to attain expected GROWTH.		02.6630
Uterine Diseases
Pathological processes involving any part of the UTERUS.		01.9610
Female Genital Neoplasms
[description not available]		01.9610
Cancer of Testis
[description not available]		01.9610
Delayed Effects, Prenatal Exposure
[description not available]		01.9610
Genital Neoplasms, Female
Tumor or cancer of the female reproductive tract (GENITALIA, FEMALE).		01.9610
Testicular Neoplasms
Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.		01.9610
Cicatrization
The formation of fibrous tissue in the place of normal tissue during the process of WOUND HEALING. It includes scar tissue formation occurring in healing internal organs as well as in the skin after surface injuries.		01.9510
Complications, Labor
[description not available]		01.9510
Complications, Pregnancy
[description not available]		01.9510
Cicatrix
The fibrous tissue that replaces normal tissue during the process of WOUND HEALING.		01.9510
Abortion, Recurrent
[description not available]		01.9810
Abortion, Habitual
Three or more consecutive spontaneous abortions.		01.9810
Hyperlipemia
[description not available]		01.9510
Hyperlipidemias
Conditions with excess LIPIDS in the blood.		01.9510
Cardiovascular Pregnancy Complications
[description not available]		01.9510
Anovulation
Suspension or cessation of OVULATION in animals or humans with follicle-containing ovaries (OVARIAN FOLLICLE). Depending on the etiology, OVULATION may be induced with appropriate therapy.		01.9510
Female Genital Diseases
[description not available]		01.9610
Genital Diseases, Female
Pathological processes involving the female reproductive tract (GENITALIA, FEMALE).		01.9610